Form 4: Gyre Therapeutics Director Exercises Stock Options
SEC Form 4 Filing
Thomas Wilson Eastling, a director at Gyre Therapeutics, exercised stock options to acquire 15,000 shares of common stock at $6.93 per share on April 16, 2025.
Summary
- On April 16, 2025, Thomas Wilson Eastling, a director of Gyre Therapeutics, exercised stock options.
- This transaction involved the acquisition of 15,000 shares of common stock at a price of $6.93 per share.
- Following the transaction, Eastling directly owns 299,652 derivative securities.
- The stock options were fully vested and are exercisable until October 31, 2033.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it simply reports a transaction. It doesn't inherently indicate positive or negative sentiment towards the company.
Positives
- The director's decision to exercise options could be interpreted as a sign of confidence in the company's future prospects.
Industry Context
Form 4 filings are standard disclosures required by the SEC when company insiders, such as directors and officers, trade in their company's stock. These filings provide transparency to the market regarding insider activity.
Key Dates
| Date | Description |
|---|---|
| 04/16/2025 | Date of the stock option exercise and acquisition of common stock. |
| 04/18/2025 | Date of signature on the Form 4 filing. |
| 10/31/2033 | Expiration date of the stock options. |
Keywords
Gyre Therapeutics, Director, Stock Options, Form 4, Beneficial Ownership, Eastling, GYRE
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.